Glp-1 Analogues Market Size, Share, By Product, Drug Class, Route of Administration, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2034

Report Code: PMI554024 | Publish Date: July 2024 | No. of Pages: 178

Glp 1 Analogues Market Companies

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi
  • AstraZeneca
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Pfizer.Inc
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • PegBio Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Zealand Pharma
  • Moderna
  • Hanmi Science

Recent News:

  • Viking's new dual GLP-1R/GIPR agonist is planned to enter phase III clinical trials as early as July 2024. VK2735 could be a direct competition for Eli Lilly's Mounjaro. Viking Therapeutics, an American biopharmaceutical company, is researching several candidates for treating metabolic illnesses. VK2735, a dual glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide (GIP) receptor agonist, is being tested as a weekly subcutaneous (SC) injection and an oral tablet for obesity management.
  • In July 2024, the MHRA authorized Semaglutide, a GLP-1 receptor agonist, to reduce the risk of serious cardiac problems in obese or overweight persons. Semaglutide is the first weight-loss medicine approved in the United Kingdom as a preventative treatment for adults with pre-existing cardiovascular disease. This GLP-1 receptor agonist has already been licensed for use in treating obesity and weight management in conjunction with diet, physical activity, and behavioral support.